Loading...
NPI 1750839262 · Jacksonville, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Ace Biomedical Labs, LLC is a clinical medical laboratory provider located in Jacksonville, Florida. This profile covers 9 Medicare and 21 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Ace Biomedical Labs, LLC |
| Address | 6444 Beach Blvd |
| City | Jacksonville |
| State | FL |
| ZIP | 32216 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 13, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.7M |
| Medicaid | $222.4K |
ACE BIOMEDICAL LABS appears to operate primarily as a high-volume COVID-19 test distributor and diagnostic lab: its Medicare activity is overwhelmingly driven by K1034 (Provision of covid-19 test, nonprescription self-administered), which shows 471.1K claims at $12 avg paid/claim for $5.7M revenue and accounts for 97.5% of the provider’s Medicare receipts; secondary Medicare activity includes nucleic acid SARS‑CoV‑2 testing (U0003) and definitive drug testing (G0481) but at orders-of-magnitude lower revenue. The Medicaid mix also shows a focus on SARS‑CoV‑2 testing (U0003) plus presumptive drug screens and related specimen-collection services, indicating the business combines high-throughput infectious disease testing with drug-testing services across payers. This pattern of code usage suggests operations oriented toward mass distribution/processing of self-administered COVID-19 tests and accompanying molecular testing services, rather than a broad clinical lab test portfolio.
Revenue concentration is extreme on both payers: the precomputed data show the top 3 Medicare codes by revenue account for 99.0% of Medicare revenue and the top 3 Medicaid codes by revenue account for 87.6% of Medicaid revenue. For Medicare this is dominated by a single code (K1034 at 97.5% of Medicare revenue), implying very high commercial sensitivity to policy or demand shifts that affect that specific code. For Medicaid the concentration is more distributed across U0003 (72.0% of Medicaid revenue) and two lower-value codes (80307 and U0005), but still reflects heavy dependence on a small set of services.
Payer mix is heavily skewed toward Medicare by scale: lifetime Medicare revenue is $5.7M versus total Medicaid revenue of $222.4K, so Medicare is the overwhelmingly larger source of billed revenue for this NPI. Medicaid activity is present and nontrivial in specific testing lines (notably U0003) but does not approach Medicare’s dollar scale, so the entity should be treated operationally as Medicare‑dominant.
K1034 is a national statistical outlier for this practice: the code ranks #82 of 30143 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), which identifies ACE BIOMEDICAL LABS as a major national dispatcher of nonprescription self-administered COVID-19 tests relative to peers. By contrast, its Medicare U0003 (613 claims, $74 avg paid/claim, $45.4K revenue) ranks #244 of 973 providers (75th percentile) and Medicare G0481 (291 claims, $153 avg paid/claim, $44.5K revenue) ranks #270 of 1766 providers (85th percentile), both described as typical or unremarkable volumes nationally — indicating the firm is dominant for retail self-test provisioning but only a modest participant in other national molecular and definitive drug-testing markets.
In-state competitive standing varies by service line: on Medicaid U0003 the provider ranks #57 of 320 in Florida (82nd percentile), showing a strong but not exceptional in-state position for high-throughput SARS‑CoV‑2 testing. For definitive drug testing under Medicaid the provider is comparatively stronger: G0481 reports 2K claims for $12K revenue and ranks #8 of 46 in-state (84th percentile), suggesting a leading role in higher-volume drug-panel services within the state despite those services representing a much smaller share of total revenue than the COVID testing line. 80307 on Medicaid (2.6K claims, $7 avg, $18.5K revenue) sits at #145 of 451 (68th percentile), indicating moderate in-state presence for presumptive drug screens.
Reimbursement profile shows very low per-claim averages for the highest-volume COVID test distribution line: K1034 carries $12 avg paid/claim on Medicare and the provider reports 1.1K Medicaid K1034 claims at $1 avg paid/claim for only $1.1K revenue, consistent with a high-volume, low-dollar-per-test retail distribution model. Similarly, Medicaid U0005 has 4.2K claims at $4 avg paid/claim ($16.8K revenue) while Medicare U0005 is smaller (612 claims, $25 avg paid/claim, $15.3K revenue), underlining differences in payer reimbursement that make Medicaid a lower-dollar channel for similar specimen-processing activity. These per-claim differentials matter for margin analysis and payer-contracting considerations.
Data quality and operational notes: several Medicaid-listed codes show claims with $0 reported revenue (for example G0482: 515 claims $0 revenue; G0483: 184 claims $0 revenue; 85025: 176 claims $0 revenue), which may reflect zero-paid adjudications, reporting timing, or bundled payment arrangements rather than absence of activity. Analysts should treat those line items as evidence of reported utilization that did not generate captured Medicaid paid dollars in the dataset and consider checking adjudication detail or supplemental state data when assessing Medicaid contribution by service.
Tenure and stability: the NPI was enumerated on 2016-09-13 (~10 years ago), indicating the entity has been on record long enough to establish persistent billing patterns; however the revenue footprint is highly concentrated in pandemic-era COVID testing codes, so historical stability should be interpreted in light of demand and policy changes around infectious disease testing and OTC/self-test coverage.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 471,080 | $10 | $5.7M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 610 | $70 | $45.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 290 | $150 | $44.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 300 | $60 | $18.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 610 | $30 | $15.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 620 | $20 | $14.1K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 30 | $140 | $4.8K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 70 | $30 | $2.4K |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 30 | $30 | $1.2K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 9 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4,780 | $30 | $162.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,640 | $10 | $18.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 4,210 | $1 | $16.8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,000 | $10 | $12K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,460 | $1 | $10.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 50 | $70 | $4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,150 | $1 | $1.1K |
| 87498 | A lab tests a patient’s specimen to provide a definitive diagnosis of meningitis by amplified probe technique. | 50 | $1 | $210 |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 40 | $1 | $90 |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 50 | $1 | $50 |
Showing 1–10 of 21
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
21 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 26 | 40 | 320 | $100 | $620K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 57 | 320 | 750 | $40 | $232.7K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 576 | 640 | 4,400 | $10 | $193.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 21 | 50 | 360 | $40 | $96.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 641 | 820 | 1,430 | $1 | $92.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 145 | 450 | 1,380 | $20 | $75.1K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 92 | 110 | 490 | $40 | $64.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 170 | 190 | 640 | $10 | $59.9K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 988 | 1,330 | 340 | $10 | $54.3K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 154 | 190 | 420 | $20 | $40.4K |
Showing 1–10 of 21
Other providers in the same ZIP code as Ace Biomedical Labs, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.